A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Taiho Oncology, Inc.
Actuate Therapeutics Inc.
SN BioScience
IMGT Co., Ltd.
Revolution Medicines, Inc.
Bristol-Myers Squibb
CARsgen Therapeutics Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Akeso
Ono Pharmaceutical Co., Ltd.
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Gilead Sciences
Lumos Pharma
Lumos Pharma
Leaf Vertical Inc.